ReviewCell2024
Mechanisms of long COVID and the path toward therapeutics.
Review in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
230 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- The Impact of Pulmonary Rehabilitation in Patients with Post-COVID-19 Syndrome: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.Stem cell research & therapy · 2026Pooled it
- Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID.Nature communications · 2025Pooled it
- Long-Term Complications of Multisystem Inflammatory Syndrome in Children and Adults Post-COVID-19: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Symptom Trajectories and Clinical Subtypes in Post-COVID-19 Condition: Systematic Review and Clustering Analysis.JMIR public health and surveillance · 2025Pooled it
- Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of Symptoms 3 Years Post-SARS-CoV-2 Infection.Journal of medical virology · 2025Pooled it
- Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.Nature communications · 2026Trial
- Trial
- Profiles of Individuals With Long COVID Reporting Persistent Cognitive Complaints.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025Trial
- Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial.Scientific reports · 2025Trial
- Pre-pandemic care-seeking patterns and subsequent diagnoses of post-COVID condition, post viral fatigue syndrome, and exhaustion disorder: a registry-based cohort study of 208,050 Swedish women.Scandinavian journal of primary health care · 2026Article
- Human brain matters: Navigating the neuropathology of COVID-19.Brain pathology (Zurich, Switzerland) · 2026Review
- Risk factors of post-COVID-19 symptoms, a cross-sectional study in patients with asthma and chronic obstructive lung disease.NPJ primary care respiratory medicine · 2026Article
- Caspase-11-mediated hyperinflammation impairs CD8+ T cell immunity and viral clearance in severe SARS-CoV-2 infection.JCI insight · 2026Article
- Neurological Manifestations of Long COVID: Current Evidence, Emerging Concepts, and Future Perspectives.Journal of clinical medicine · 2026Review
- A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study.Integrative medicine research · 2026Article
- When do infections lead to long COVID? Scientists close in on triggers and treatments for post-viral syndromes.Nature · 2026Article
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symptoms following infection with SARS-CoV-2, is a newly recognized infection-associated chronic condition that causes disability in some people. Substantial progress has been made in defining its epidemiology, biology, and pathophysiology. However, there is no cure for the tens of millions of people believed to be experiencing long COVID, and industry engagement in developing therapeutics has been limited. Here, we review the current state of knowledge regarding the biology and pathophysiology of long COVID, focusing on how the proposed mechanisms explain the physiology of the syndrome and how they provide a rationale for the implementation of a broad experimental medicine and clinical trials agenda. Progress toward preventing and curing long COVID and other infection-associated chronic conditions will require deep and sustained investment by funders and industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.